{"gene":"SSTR1","run_date":"2026-04-28T20:42:08","timeline":{"discoveries":[{"year":1992,"finding":"SSTR1 was cloned and functionally characterized as a seven-transmembrane G protein-coupled receptor with 391 amino acids. Stably transfected CHO cells expressing SSTR1 exhibited specific, high-affinity somatostatin binding (higher affinity for somatostatin-14 than somatostatin-28), establishing SSTR1 as a bona fide somatostatin receptor.","method":"cDNA cloning, stable transfection in CHO cells, radioligand binding assays, RNA blotting","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — original cloning with functional expression, radioligand binding, and tissue distribution in multiple cell systems","pmids":["1346068"],"is_preprint":false},{"year":1993,"finding":"SSTR1 gene was chromosomally mapped to human chromosome 14q13, and a simple tandem repeat polymorphism was identified within the SSTR1 gene.","method":"Somatic cell hybrid panel segregation analysis, fluorescence in situ hybridization (FISH)","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 — two orthogonal mapping methods confirming chromosomal localization","pmids":["8449518"],"is_preprint":false},{"year":1993,"finding":"Human SSTR1 stably expressed in HEK 293 cells couples to inhibition of forskolin-induced cAMP production, demonstrating functional coupling to adenylyl cyclase inhibition.","method":"Stable transfection in HEK293 cells, cAMP measurement assay","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 2 — functional coupling in heterologous expression system, replicated across labs","pmids":["8405411"],"is_preprint":false},{"year":1994,"finding":"SSTR1 stably expressed in CHO-K1 cells couples to inhibition of adenylyl cyclase via pertussis toxin-sensitive G proteins (Gi), and this coupling requires GTP. Specifically, antiserum against Giα3 (but not Giα1/Giα2) blocked SSTR1-mediated inhibition of adenylyl cyclase, identifying Giα3 as the dominant G protein coupling partner. SSTR1 additionally couples to stimulation of inositol 1,4,5-trisphosphate (IP3) formation, also through a pertussis toxin-sensitive mechanism.","method":"Stable transfection in CHO cells, cAMP and IP3 measurement assays, pertussis toxin pretreatment, specific Giα antiserum blockade","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal assays with specific antibody blockade identifying Giα3 as coupling partner","pmids":["7524497"],"is_preprint":false},{"year":1994,"finding":"SSTR1 and SSTR2 stably expressed in CHO-K1 cells both inhibit adenylyl cyclase by approximately 35% via pertussis toxin-sensitive G proteins (Gi). Both SS14 and SS28 activate SSTR1 with high affinity (nanomolar ED50), whereas the synthetic analog MK678 does not activate SSTR1, establishing a pharmacological distinction between the two receptor subtypes.","method":"Stable transfection in CHO-K1 cells, adenylyl cyclase assay, pertussis toxin pretreatment, radioligand binding","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — functional coupling confirmed with pertussis toxin and GTP-dependence, replicated across labs","pmids":["7907016"],"is_preprint":false},{"year":1994,"finding":"Somatostatin activation of SSTR1 stimulates phosphotyrosine phosphatase (PTP) activity in CHO-K1 cells with an EC50 of ~70 nM. This activation is sensitive to pertussis toxin. PTP stimulation in pituitary cell lines correlates with endogenous SSTR1 expression, suggesting SSTR1 couples to PTP stimulation as an effector pathway distinct from adenylyl cyclase inhibition.","method":"Stable transfection in CHO-K1 cells, phosphotyrosine phosphatase activity assay, pertussis toxin treatment, comparison with endogenous pituitary cell expression","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — functional assay in heterologous and endogenous cell systems with pertussis toxin validation","pmids":["7854346"],"is_preprint":false},{"year":1994,"finding":"SSTR1 and SSTR2 display distinct signaling properties when stably expressed in mouse fibroblast Ltk- or transiently in HEK293 cells. Both subtypes mediate somatostatin inhibition of cAMP via pertussis toxin-sensitive G proteins. However, only SSTR1 mediates somatostatin inhibition of Na+/H+ exchange activity, and this effect is pertussis toxin-insensitive. Chimeric receptor analysis localized the structural determinant for SSTR1-specific Na+/H+ exchanger coupling to sequences spanning the second through sixth hydrophobic domains (including second and third cytoplasmic loops), outside the third cytoplasmic loop alone.","method":"Stable and transient transfection, cAMP assay, Na+/H+ exchange activity assay, pertussis toxin treatment, chimeric receptor construction and functional analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — chimeric receptor mutagenesis with multiple functional readouts identifying structural determinants of subtype-specific signaling","pmids":["8144617"],"is_preprint":false},{"year":1994,"finding":"In cells expressing SSTR1 or SSTR2, somatostatin analogues RC-160 and SMS-201-995 stimulate tyrosine phosphatase activity and inhibit serum-stimulated cell proliferation. In SSTR1-expressing cells, RC-160 (but not SMS-201-995) induced tyrosine phosphatase stimulation, consistent with RC-160's higher affinity for SSTR1. The correlation between receptor-binding affinity, tyrosine phosphatase stimulation, and antiproliferative potency implicates tyrosine phosphatase as a transducer of the SSTR1-mediated growth inhibition signal.","method":"Transfection in COS-7 and NIH 3T3 cells, radioligand competition binding assays, tyrosine phosphatase activity assay, cell proliferation assay (serum-stimulated), adenylyl cyclase assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple functional readouts in two cell systems with pharmacological correlation between binding affinity and functional potency","pmids":["7907795"],"is_preprint":false},{"year":1996,"finding":"The first selective SSTR1 agonist, des-AA1,2,5-[DTrp8, IAmp9]SRIF (and its radiolabeled analog), was developed. This ligand binds human SSTR1 with an affinity of 1.8 nM (Kd ~0.5 nM) but does not bind other SSTR subtypes. GTPγS reduced binding of the selective analog to SSTR1 (an effect prevented by pertussis toxin), but did not affect SRIF binding to SSTR1, indicating the selective agonist binds SSTR1 in a functionally distinct, G protein-coupled conformation.","method":"Radioligand competition binding assays in COS-7 cells expressing human SSTR1, saturation binding, GTPγS and pertussis toxin modulation of binding","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 2 — selective pharmacological tool development with G protein coupling validation and saturation binding characterization","pmids":["8786539"],"is_preprint":false},{"year":1997,"finding":"When SSTR1 and SSTR2 are individually expressed in rat pituitary GH12C1 and F4C1 cells lacking endogenous SSTRs: both couple to inhibition of Ca2+ influx and membrane hyperpolarization via pertussis toxin-sensitive G proteins; both mediate adenylyl cyclase inhibition via PTx-sensitive pathways; but only SSTR2 (not SSTR1) stimulates phospholipase C and increases intracellular Ca2+ from intracellular stores. Chimeric receptor analysis showed that sequences beyond the three intracellular loops (i.e., transmembrane domains) are required for SSTR2's unique PLC coupling.","method":"Stable transfection in pituitary GH12C1 and F4C1 cells lacking endogenous SSTRs, Ca2+ imaging, membrane potential measurements, cAMP assay, IP3/PLC assay, pertussis toxin treatment, chimeric receptor construction","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — chimeric receptor mutagenesis with multiple functional assays in cell lines lacking endogenous receptors","pmids":["9228036"],"is_preprint":false},{"year":1999,"finding":"SSTR1 stably expressed in CHO-K1 cells activates ERK (MAP kinase) in response to somatostatin, paradoxically augmenting fibroblast growth factor-stimulated ERK activity while antagonizing proliferation. SSTR1-mediated ERK activation requires: (1) pertussis toxin-sensitive Gβγ subunits, (2) Ras, (3) phosphatidylinositol 3-kinase, (4) Raf-1 kinase, and (5) the protein tyrosine phosphatase SHP-2. This ERK activation results in upregulation of the CDK inhibitor p21(cip1/WAF1), linking the SSTR1→SHP-2→ERK axis to the antiproliferative mechanism.","method":"Stable transfection in CHO-K1 cells, ERK activity assay (MAP kinase assay), pertussis toxin treatment, dominant-negative Ras and PI3K constructs, Raf-1 inhibition, SHP-2 manipulation, p21 immunoblotting","journal":"Molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic epistasis tools (dominant negatives) with defined pathway placement and molecular readout","pmids":["9892010"],"is_preprint":false},{"year":1999,"finding":"Structural determinants of SSTR1-selective ligand binding were mapped using chimeric SSTR1/SSTR2 receptors and site-directed mutagenesis. Asp137 in transmembrane domain 3 (TM3) of SSTR1 forms an ion pair with the IAmp9 moiety of selective agonist CH275; mutation Asp137→Asn caused loss of binding and reduced potency. Leu107 in TM2 of SSTR1 provides a hydrophobic interaction with the isopropyl group of IAmp; Leu107→Phe substitution reduced CH275 affinity 20-fold without affecting SS affinity. Reciprocal Phe→Leu in a chimeric receptor restored CH275 affinity. These findings define Asp137 (TM3) and Leu107 (TM2) as key determinants of SSTR1 ligand selectivity.","method":"Chimeric SSTR1/SSTR2 receptor construction, site-directed mutagenesis (Asp137Asn, Leu107Phe), radioligand binding assays, microphysiometry (extracellular acidification rate)","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — reciprocal mutagenesis with functional validation identifies specific binding determinants","pmids":["10329447"],"is_preprint":false},{"year":1999,"finding":"Using the silicon-based Cytosensor microphysiometer to measure extracellular acidification rate (ECAR) in pituitary F4C1 cells (lacking endogenous SSTRs), SSTR1 activation by somatostatin uniquely causes a decrease in ECAR (not previously observed for any receptor), while SSTR2 causes a biphasic ECAR response (increase then decrease). Both SSTR1- and SSTR2-mediated ECAR decreases are abolished by pertussis toxin. The ECAR responses involve both amiloride-sensitive and amiloride-insensitive Na+-dependent acid transport mechanisms, and removal of extracellular Na+ abolishes responses.","method":"Stable transfection in F4C1 pituitary cells, Cytosensor microphysiometry (ECAR measurement), pertussis toxin pretreatment, pharmacological inhibitors (methylisobutylamiloride), Na+-free conditions, receptor-selective agonists (MK678, CH275)","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 2 — novel biosensor readout with pharmacological dissection in cells lacking endogenous SSTRs","pmids":["10405760"],"is_preprint":false},{"year":2000,"finding":"SSTR subtypes form homo- and heterodimers. Ligand activation induces SSTR1 homodimerization and SSTR1/SSTR5 heterodimerization as demonstrated by FRET analysis, pharmacological binding studies, and biochemical approaches. Dimerization alters functional properties including ligand binding affinity and agonist-induced receptor internalization. When SSTR1 and SSTR5 are coexpressed in CHO-K1 cells and treated with agonist, they internalize together into cytoplasmic vesicles. SSTR5 forms heterodimers with SSTR1 but not SSTR4, indicating selectivity of the heterodimerization process.","method":"Fluorescence resonance energy transfer (FRET), double-label confocal fluorescence microscopy, co-immunoprecipitation, pharmacological binding assays, transfected mutant and wild-type receptors in CHO-K1 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (FRET, confocal imaging, biochemistry) with functional consequences of dimerization","pmids":["10713101"],"is_preprint":false},{"year":2000,"finding":"SSTR1-mediated inhibition of cell proliferation in CHO-K1 cells correlates with activation of the MAP kinase cascade. The antiproliferative signal of SSTR1 requires Gβγ subunits from a pertussis toxin-sensitive G protein, Ras, Raf-1, PI3K, c-Src (a cytosolic tyrosine kinase), and SHP-2 (protein tyrosine phosphatase) to activate ERK. SHP-2 activates upstream kinases requiring tyrosine dephosphorylation (such as c-Src). Somatostatin and bFGF synergistically activate ERK via SSTR1, resulting in upregulation of p21cip/WAF1 as the molecular effector of antiproliferative activity.","method":"Stable transfection in CHO-K1 cells, ERK/MAP kinase activity assays, pertussis toxin, dominant-negative constructs for Ras/Raf/PI3K/c-Src/SHP-2, p21 expression analysis, proliferation assays","journal":"Journal of physiology, Paris","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic review of prior experimental data confirming SSTR1→Gβγ→Ras→Raf→PI3K→c-Src→SHP-2→ERK→p21 pathway, single lab","pmids":["11088001"],"is_preprint":false},{"year":2003,"finding":"SSTR1 selective activation by BIM-23926 in primary cultures from GH- and PRL-secreting human pituitary adenomas (expressing SSTR1 mRNA) inhibits GH secretion (~32%), PRL secretion (~20%), and reduces cell viability (~20%). The degree of inhibition correlates with SSTR1 mRNA levels, establishing a functional role for SSTR1 in suppressing hormone secretion and cell viability in pituitary adenoma cells.","method":"Primary culture of human pituitary adenoma cells, SSTR1-selective agonist (BIM-23926) treatment, RIA/hormone secretion assays, cell viability assay, quantitative RT-PCR for SSTR1 mRNA","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — functional assay with selective pharmacological tool in primary human cells, single lab","pmids":["12788890"],"is_preprint":false},{"year":2004,"finding":"Activation of hSSTR5 but not hSSTR1 is required for SSTR1/SSTR5 heterodimer formation. In cells co-expressing hSSTR1 and hSSTR5, treatment with SSTR5-selective agonist (but not SSTR1-selective agonist) induced heterodimerization, accompanied by increased adenylyl cyclase coupling efficiency. The C-terminal tail of hSSTR5 was identified as a structural determinant of heterodimer formation via chimeric receptor analysis. In contrast, hSSTR1 alone remains monomeric regardless of agonist treatment.","method":"Photobleaching FRET microscopy, Western blot, stable co-expression of hSSTR1 and hSSTR5 in live cells, C-tail chimeric receptors, adenylyl cyclase assay, subtype-selective agonist treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — pbFRET and Western blot with chimeric receptor mutagenesis identifying the C-tail of SSTR5 as the dimerization determinant","pmids":["15247250"],"is_preprint":false},{"year":2006,"finding":"SSTR1 knockout mice display altered glucose homeostasis: at 3 months, SSTR1-/- mice have reduced body weight with growth retardation; isolated perfused pancreata show increased basal insulin secretion in vitro, but systemic insulin levels are decreased due to significantly higher insulin clearance rate; SSTR1-/- mice are glucose intolerant at 3 months but show increased glucose tolerance with exaggerated insulin response at 12 months. Immunohistochemistry showed decreased somatostatin staining and decreased SSTR5 expression in SSTR1-/- islets, suggesting SSTR1 regulates SSTR5 expression and coordinates insulin secretion and glucose homeostasis.","method":"SSTR1 knockout mouse model, intraperitoneal glucose tolerance test, isolated perfused pancreas model, islet culture, immunohistochemistry, insulin RIA","journal":"Molecular and cellular endocrinology","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with multiple physiological readouts across multiple ages","pmids":["16406265"],"is_preprint":false},{"year":2004,"finding":"Double-gene ablation of SSTR1 and SSTR5 in mice results in islet hyperplasia, hyperinsulinemia, and improved glucose tolerance—a phenotype distinct from single-gene ablation of either receptor alone (which causes diabetes). SSTR1/5-/- islets show no response to somatostatin peptides in vitro, confirming ablation. Double-KO mice show increased basal and glucose-stimulated insulin secretion in vitro and exaggerated late-phase insulin secretion in vivo. This demonstrates that SSTR1 and SSTR5 act coordinately and non-redundantly to regulate insulin secretion and glucose homeostasis.","method":"SSTR1/SSTR5 double-knockout mouse generation, intraperitoneal glucose tolerance test, isolated perfused mouse pancreas, islet culture with somatostatin treatment, immunohistochemistry","journal":"Surgery","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis (double KO vs single KO) with multiple functional readouts establishing coordinate regulation","pmids":["15349106"],"is_preprint":false},{"year":2009,"finding":"In C6 rat glioma cells in vivo (nude mouse xenograft model), selective SSTR1 agonist BIM-23745 inhibits tumor growth, reduces intratumoral neovascularization, suppresses Ki-67 expression, decreases ERK1/2 phosphorylation, and upregulates p27(Kip1). Combined activation of SSTR1 and SSTR2 (BIM-23704) shows synergistic antiproliferative and antiangiogenic activity exceeding SSTR5 agonist effects. Only modest caspase-3 activation is observed, indicating the mechanism is primarily cytostatic rather than apoptotic.","method":"Nude mouse C6 glioma xenograft model, selective SSTR1 agonist (BIM-23745) and bi-selective compounds, tumor growth measurement, immunohistochemistry for Ki-67, phospho-ERK1/2, p27Kip1, and caspase-3","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo loss/gain of function with selective pharmacological tools and molecular readouts, single lab","pmids":["19706788"],"is_preprint":false},{"year":2014,"finding":"Following intracerebral hemorrhage (ICH) in adult rats, SSTR1 expression is markedly upregulated in neurons surrounding the hematoma. SSTR1 co-localizes with active caspase-3 (pro-apoptotic) and inversely with Bcl-2 (anti-apoptotic) in a time-dependent manner. Knockdown of SSTR1 in PC12 cells specifically reduces neuronal apoptosis. These data identify SSTR1 as a contributor to post-ICH neuronal apoptosis, coupled to caspase-3 activation and reduction of Bcl-2.","method":"Rat ICH model (caudate putamen), Western blot, immunohistochemistry, double-labeled immunofluorescence, SSTR1 siRNA knockdown in PC12 cells, behavioral testing","journal":"Cellular and molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2–3 — in vivo model with knockdown validation in cell culture; single lab with co-localization and functional readout","pmids":["25035058"],"is_preprint":false},{"year":2016,"finding":"In colorectal cancer (CRC), SSTR1-expressing neuroendocrine cells regulate cancer stem cell (ALDH+) quiescence via paracrine signaling. When SSTR1+ cells are co-cultured with ALDH+ cancer stem cells in transwell assays, sphere formation and proliferation of ALDH+ cells are inhibited. ALDH+ cells themselves lack SST and SSTR1 expression, confirming the paracrine mechanism. Inhibition of SSTR1 signaling by cycloSST (a somatostatin antagonist) decreases ALDH+ cell population size and sphere formation, and the ALDH+/SSTR1+ ratio inversely correlates with growth dynamics.","method":"Flow cytometry (ALDH, SSTR1 quantification), transwell co-culture assays, sphere formation assay, proliferation assay (doubling time), exogenous SST and cycloSST treatment, primary normal/tumor tissue analysis, CRC cell lines","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2–3 — transwell paracrine assay with pharmacological manipulation; multiple CRC cell lines and primary tissue but single lab","pmids":["27927191"],"is_preprint":false},{"year":2020,"finding":"In a MPTP-induced Parkinson's disease mouse model and MPP+-treated MN9D dopaminergic cells, the lncRNA HOTAIR is upregulated while SSTR1 is downregulated. HOTAIR binds to the SSTR1 promoter and recruits DNA methyltransferases to increase SSTR1 promoter methylation, thereby suppressing SSTR1 expression. Overexpression of HOTAIR or silencing of SSTR1 enhances dopaminergic neuron apoptosis and exacerbates dyskinesia; conversely, reduced HOTAIR/restored SSTR1 is neuroprotective. The downstream effect of SSTR1 suppression operates through activation of the ERK1/2 signaling axis.","method":"MPTP mouse model and MPP+ cell model of PD, HOTAIR overexpression/knockdown, SSTR1 knockdown/overexpression, chromatin immunoprecipitation (ChIP) for HOTAIR binding to SSTR1 promoter, bisulfite sequencing for methylation, Western blot (ERK1/2), cell viability and apoptosis assays, behavioral testing","journal":"Molecular therapy. Nucleic acids","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and methylation analysis with epistatic rescue experiments linking HOTAIR→SSTR1 methylation→ERK1/2→apoptosis; single lab","pmids":["32927363"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structures of Gi-coupled SSTR1 were determined bound to the FDA-approved panagonist pasireotide and the SSTR1-selective small molecule agonist L-797591. The structures reveal that pasireotide occupies an extended binding pocket conserved across SSTRs, distinct from the binding mode of SST14, octreotide, and lanreotide. The SSTR1 orthosteric pocket accommodates divergent agonists through dynamic conformational changes. Key residues determining SSTR1 vs. SSTR3 ligand selectivity were identified across the orthosteric pocket, and mutagenesis analyses validated these structural determinants. The structures also reveal the molecular mechanism of receptor activation and G protein coupling.","method":"Cryo-electron microscopy (cryo-EM) structure determination of Gi-coupled SSTR1 and SSTR3, site-directed mutagenesis, functional assays validating binding and activation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structures with mutagenesis validation, revealing molecular basis of ligand recognition and receptor activation","pmids":["39361640"],"is_preprint":false}],"current_model":"SSTR1 is a seven-transmembrane Gi-coupled receptor (primarily Giα3) that, upon somatostatin binding, inhibits adenylyl cyclase and stimulates phosphotyrosine phosphatase (PTP) activity—including SHP-2—which in turn activates a Gβγ→Ras→PI3K→c-Src→Raf-1→ERK cascade leading to p21(cip1/WAF1) upregulation and cell growth arrest; uniquely among SSTRs, SSTR1 also inhibits Na+/H+ exchange via a pertussis toxin-insensitive mechanism, can form selective heterodimers with SSTR5 (requiring SSTR5 C-tail conformational changes) that alter receptor signaling and internalization, and plays an essential role in pancreatic insulin secretion and glucose homeostasis as demonstrated by knockout models; structural basis for its ligand recognition has been revealed by cryo-EM structures showing a conserved extended binding pocket with SSTR1-specific residues (Asp137 in TM3, Leu107 in TM2) governing selective agonist accommodation."},"narrative":{"teleology":[{"year":1992,"claim":"Molecular cloning of SSTR1 established it as a 391-amino-acid seven-transmembrane receptor with high-affinity somatostatin binding, resolving the molecular identity of somatostatin receptor subtypes.","evidence":"cDNA cloning with stable expression in CHO cells and radioligand binding assays","pmids":["1346068"],"confidence":"High","gaps":["No effector coupling or signaling pathway identified","Tissue-specific function unknown"]},{"year":1994,"claim":"Functional coupling studies revealed that SSTR1 inhibits adenylyl cyclase via Giα3, stimulates phosphotyrosine phosphatase activity, and—uniquely among SSTRs—inhibits Na⁺/H⁺ exchange through a pertussis toxin-insensitive mechanism, establishing SSTR1 as a multi-effector receptor with subtype-specific signaling.","evidence":"Heterologous expression in CHO-K1 and Ltk⁻ cells with cAMP, PTP, and NHE assays; Giα-specific antiserum blockade; chimeric receptor analysis localizing NHE coupling to TM2-TM6 domains","pmids":["7524497","7854346","8144617","7907795"],"confidence":"High","gaps":["Identity of the specific phosphotyrosine phosphatase was not determined","Molecular mechanism of PTx-insensitive NHE coupling unresolved","Downstream consequences of PTP activation for cell fate unknown"]},{"year":1999,"claim":"The antiproliferative signaling cascade downstream of SSTR1 was delineated as a Gβγ→Ras→PI3K→c-Src→Raf-1→ERK pathway dependent on SHP-2, culminating in p21(cip1/WAF1) upregulation and cell-cycle arrest, resolving the paradox of growth-inhibitory ERK activation.","evidence":"Dominant-negative constructs for Ras, Raf, PI3K, c-Src, and SHP-2 in stably transfected CHO-K1 cells with ERK activity and p21 immunoblotting","pmids":["9892010","11088001"],"confidence":"High","gaps":["Pathway validated only in CHO-K1 cells; relevance to endogenous SSTR1-expressing tissues not confirmed","Mechanism by which SHP-2 activates c-Src not fully defined"]},{"year":1999,"claim":"Mutagenesis identified Asp137 in TM3 and Leu107 in TM2 as critical determinants of SSTR1-selective agonist recognition, providing the first structural basis for receptor subtype selectivity.","evidence":"Chimeric SSTR1/SSTR2 receptors and site-directed mutagenesis with radioligand binding and microphysiometry in transfected cells","pmids":["10329447"],"confidence":"High","gaps":["No high-resolution structural data at this time","Additional residues contributing to full selectivity profile unexplored"]},{"year":2000,"claim":"Discovery that SSTR1 forms ligand-induced homodimers and selective heterodimers with SSTR5 (but not SSTR4), with heterodimerization altering binding affinity and co-internalization, established receptor oligomerization as a regulatory mechanism for SSTR signaling.","evidence":"FRET, co-immunoprecipitation, and confocal microscopy in CHO-K1 cells co-expressing tagged receptors","pmids":["10713101","15247250"],"confidence":"High","gaps":["Physiological relevance of heterodimerization in native tissues not demonstrated","Downstream signaling consequences of dimers vs. monomers incompletely characterized"]},{"year":2004,"claim":"Single and double knockout of SSTR1 and SSTR5 in mice revealed non-redundant, coordinate regulation of insulin secretion and glucose homeostasis, establishing an essential physiological role for SSTR1 in pancreatic endocrine function.","evidence":"SSTR1⁻/⁻ and SSTR1/5⁻/⁻ mice with glucose tolerance tests, perfused pancreas, islet culture, and immunohistochemistry","pmids":["16406265","15349106"],"confidence":"High","gaps":["Mechanism by which SSTR1 loss alters SSTR5 expression unknown","Human relevance of knockout phenotypes not established"]},{"year":2009,"claim":"In vivo anti-tumor activity of SSTR1 was demonstrated in glioma xenografts, where selective SSTR1 activation suppressed tumor growth, neovascularization, and ERK phosphorylation while upregulating p27(Kip1), confirming cytostatic rather than apoptotic mechanisms.","evidence":"Nude mouse C6 glioma xenograft with SSTR1-selective agonist BIM-23745, immunohistochemistry for Ki-67, p-ERK, p27, and caspase-3","pmids":["19706788"],"confidence":"Medium","gaps":["Single tumor model and single lab","Antiangiogenic mechanism not molecularly defined","Switch from ERK-dependent p21 (CHO cells) to p27 (glioma) upregulation unexplained"]},{"year":2024,"claim":"Cryo-EM structures of Gi-coupled SSTR1 bound to pasireotide and L-797591 revealed the atomic basis of the orthosteric binding pocket, confirming mutagenesis-predicted selectivity determinants and providing a structural framework for subtype-selective drug design.","evidence":"Cryo-EM structure determination with site-directed mutagenesis validation and functional assays","pmids":["39361640"],"confidence":"High","gaps":["No structure of SSTR1 in apo or antagonist-bound state","Structural basis of SSTR1/SSTR5 heterodimerization unknown","Mechanism of PTx-insensitive NHE coupling not structurally resolved"]},{"year":null,"claim":"Key unresolved questions include the structural basis for SSTR1's unique pertussis toxin-insensitive coupling to Na⁺/H⁺ exchange, the physiological significance of SSTR1/SSTR5 heterodimerization in native human tissues, and the molecular mechanism by which SSTR1 loss alters SSTR5 expression in pancreatic islets.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model for PTx-insensitive NHE pathway coupling","SSTR1/SSTR5 heterodimer not demonstrated in native tissue","Human genetic studies linking SSTR1 variants to metabolic disease absent"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,3,8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,7,10,14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,13,16]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,10,14,23]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[13,16]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[17,18]}],"complexes":[],"partners":["SSTR5","GNAI3","PTPN11","SRC"],"other_free_text":[]},"mechanistic_narrative":"SSTR1 is a Gi-coupled somatostatin receptor that transduces antiproliferative, secretory-inhibitory, and metabolic signals through multiple effector pathways. Upon somatostatin binding, SSTR1 inhibits adenylyl cyclase via pertussis toxin-sensitive Giα3 and stimulates phosphotyrosine phosphatase (SHP-2) activity, which feeds into a Gβγ→Ras→PI3K→c-Src→Raf-1→ERK cascade culminating in p21(cip1/WAF1) upregulation and cell-cycle arrest [PMID:9892010, PMID:7524497, PMID:7854346]. Uniquely among somatostatin receptors, SSTR1 inhibits Na⁺/H⁺ exchange through a pertussis toxin-insensitive mechanism structurally mapped to transmembrane domains 2–6, forms selective ligand-dependent heterodimers with SSTR5 that alter signaling efficiency, and coordinates with SSTR5 to regulate pancreatic insulin secretion and glucose homeostasis as demonstrated by single- and double-knockout mouse models [PMID:8144617, PMID:10713101, PMID:15349106, PMID:16406265]. Cryo-EM structures of Gi-coupled SSTR1 bound to pasireotide and the SSTR1-selective agonist L-797591 reveal an extended orthosteric pocket with subtype-specific residues including Asp137 (TM3) and Leu107 (TM2) governing selective agonist accommodation [PMID:39361640, PMID:10329447]."},"prefetch_data":{"uniprot":{"accession":"P30872","full_name":"Somatostatin receptor type 1","aliases":["SRIF-2"],"length_aa":391,"mass_kda":42.7,"function":"Receptor for somatostatin with higher affinity for somatostatin-14 than -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P30872/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SSTR1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SSTR1","total_profiled":1310},"omim":[{"mim_id":"609445","title":"RELAXIN/INSULIN-LIKE FAMILY PEPTIDE RECEPTOR 3; RXFP3","url":"https://www.omim.org/entry/609445"},{"mim_id":"600140","title":"CREB-BINDING PROTEIN; CREBBP","url":"https://www.omim.org/entry/600140"},{"mim_id":"300942","title":"CHROMOSOME Xq26.3 DUPLICATION SYNDROME","url":"https://www.omim.org/entry/300942"},{"mim_id":"182455","title":"SOMATOSTATIN RECEPTOR 5; SSTR5","url":"https://www.omim.org/entry/182455"},{"mim_id":"182454","title":"SOMATOSTATIN RECEPTOR 4; SSTR4","url":"https://www.omim.org/entry/182454"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Vesicles","reliability":"Uncertain"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":8.8},{"tissue":"intestine","ntpm":13.0},{"tissue":"stomach 1","ntpm":20.5}],"url":"https://www.proteinatlas.org/search/SSTR1"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P30872","domains":[{"cath_id":"1.20.1070.10","chopping":"58-341","consensus_level":"high","plddt":91.275,"start":58,"end":341}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P30872","model_url":"https://alphafold.ebi.ac.uk/files/AF-P30872-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P30872-F1-predicted_aligned_error_v6.png","plddt_mean":78.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SSTR1","jax_strain_url":"https://www.jax.org/strain/search?query=SSTR1"},"sequence":{"accession":"P30872","fasta_url":"https://rest.uniprot.org/uniprotkb/P30872.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P30872/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P30872"}},"corpus_meta":[{"pmid":"7907795","id":"PMC_7907795","title":"Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7907795","citation_count":322,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8012966","id":"PMC_8012966","title":"Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.","date":"1994","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8012966","citation_count":294,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7698537","id":"PMC_7698537","title":"Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue.","date":"1994","source":"Digestion","url":"https://pubmed.ncbi.nlm.nih.gov/7698537","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9892010","id":"PMC_9892010","title":"Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1).","date":"1999","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9892010","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8170498","id":"PMC_8170498","title":"Localization of somatostatin (SRIF) SSTR-1, SSTR-2 and SSTR-3 receptor mRNA in rat brain by in situ hybridization.","date":"1994","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8170498","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9322965","id":"PMC_9322965","title":"Expression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy.","date":"1997","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9322965","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8190266","id":"PMC_8190266","title":"Differential expression of messenger RNAs for somatostatin receptor subtypes SSTR1, SSTR2 and SSTR3 in adult rat brain: analysis by RNA blotting and in situ hybridization histochemistry.","date":"1994","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/8190266","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15961235","id":"PMC_15961235","title":"Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis.","date":"2005","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15961235","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7854346","id":"PMC_7854346","title":"The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells.","date":"1994","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/7854346","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22829710","id":"PMC_22829710","title":"Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry.","date":"2012","source":"Acta histochemica et cytochemica","url":"https://pubmed.ncbi.nlm.nih.gov/22829710","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8786539","id":"PMC_8786539","title":"Development of a selective agonist at the somatostatin receptor subtype sstr1.","date":"1996","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/8786539","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26722517","id":"PMC_26722517","title":"Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26722517","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8144617","id":"PMC_8144617","title":"Subtype-specific signaling mechanisms of somatostatin receptors SSTR1 and SSTR2.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8144617","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7777168","id":"PMC_7777168","title":"Patterns of expression of SSTR1 and SSTR2 somatostatin receptor subtypes in the hypothalamus of the adult rat: relationship to neuroendocrine function.","date":"1995","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/7777168","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11088001","id":"PMC_11088001","title":"Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2.","date":"2000","source":"Journal of physiology, Paris","url":"https://pubmed.ncbi.nlm.nih.gov/11088001","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7907016","id":"PMC_7907016","title":"The somatostatin receptors SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase in Chinese hamster ovary cells via pertussis toxin-sensitive pathways.","date":"1994","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7907016","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7781706","id":"PMC_7781706","title":"Pharmacological identity between somatostatin SS-2 binding sites and SSTR-1 receptors.","date":"1995","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7781706","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9228036","id":"PMC_9228036","title":"Both overlapping and distinct signaling pathways for somatostatin receptor subtypes SSTR1 and SSTR2 in pituitary cells.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9228036","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7524497","id":"PMC_7524497","title":"Multiple effector coupling of somatostatin receptor subtype SSTR1.","date":"1994","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7524497","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27927191","id":"PMC_27927191","title":"Somatostatin signaling via SSTR1 contributes to the quiescence of colon cancer stem cells.","date":"2016","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27927191","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15349106","id":"PMC_15349106","title":"Double-gene ablation of SSTR1 and SSTR5 results in hyperinsulinemia and improved glucose tolerance in mice.","date":"2004","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/15349106","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17626271","id":"PMC_17626271","title":"Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus.","date":"2007","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17626271","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19706788","id":"PMC_19706788","title":"Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice.","date":"2009","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19706788","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31873798","id":"PMC_31873798","title":"Somatostatin receptors (SSTR1-5) on inhibitory interneurons in the barrel cortex.","date":"2019","source":"Brain structure & function","url":"https://pubmed.ncbi.nlm.nih.gov/31873798","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20140708","id":"PMC_20140708","title":"Molecular characterization and polymorphisms of the caprine Somatostatin (SST) and SST Receptor 1 (SSTR1) genes that are linked with growth traits.","date":"2010","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/20140708","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20529830","id":"PMC_20529830","title":"SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.","date":"2010","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/20529830","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16406265","id":"PMC_16406265","title":"Alterations in glucose homeostasis in SSTR1 gene-ablated mice.","date":"2006","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16406265","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33899156","id":"PMC_33899156","title":"Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential.","date":"2021","source":"Neurosurgical review","url":"https://pubmed.ncbi.nlm.nih.gov/33899156","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10329447","id":"PMC_10329447","title":"Structural basis for the binding specificity of a SSTR1-selective analog of somatostatin.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10329447","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10405760","id":"PMC_10405760","title":"Identification of distinct signalling pathways for somatostatin receptors SSTR1 and SSTR2 as revealed by microphysiometry.","date":"1999","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/10405760","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25035058","id":"PMC_25035058","title":"Upregulated expression of SSTR1 is involved in neuronal apoptosis and is coupled to the reduction of bcl-2 following intracerebral hemorrhage in adult rats.","date":"2014","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/25035058","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16183496","id":"PMC_16183496","title":"Transfection of SSTR-1 and SSTR-2 inhibits Panc-1 cell proliferation and renders Panc-1 cells responsive to somatostatin analogue.","date":"2005","source":"Journal of the American College of Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/16183496","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12502754","id":"PMC_12502754","title":"Localization of messenger ribonucleic acids for somatostatin receptor subtypes (sstr1-5) in the rat adrenal gland.","date":"2003","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/12502754","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25861128","id":"PMC_25861128","title":"Expressions of Somatostatin Receptor Subtypes (SSTR-1, 2, 3, 4 and 5) in Neuroblastic Tumors; Special Reference to Clinicopathological Correlations with International Neuroblastoma Pathology Classification and Outcomes.","date":"2014","source":"Acta histochemica et cytochemica","url":"https://pubmed.ncbi.nlm.nih.gov/25861128","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22581439","id":"PMC_22581439","title":"Immunohistochemical distribution of somatostatin and somatostatin receptor subtypes (SSTR1-5) in hypothalamus of ApoD knockout mice brain.","date":"2012","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/22581439","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32875251","id":"PMC_32875251","title":"Molecular-Level Understanding of the Somatostatin Receptor 1 (SSTR1)-Ligand Binding: A Structural Biology Study Based on Computational Methods.","date":"2020","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/32875251","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24634938","id":"PMC_24634938","title":"Somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5)expression in hepatocellular carcinoma.","date":"2013","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/24634938","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35052417","id":"PMC_35052417","title":"Identification of Somatostatin Receptor Subtype 1 (SSTR1) Gene Polymorphism and Their Association with Growth Traits in Hulun Buir Sheep.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/35052417","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32927363","id":"PMC_32927363","title":"HOTAIR Accelerates Dyskinesia in a MPTP-Lesioned Mouse Model of PD via SSTR1 Methylation-Mediated ERK1/2 Axis.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/32927363","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25149275","id":"PMC_25149275","title":"Expression and localization of somatostatin receptor types 3, 4 and 5 in the wild-type, SSTR1 and SSTR1/SSTR2 knockout mouse cochlea.","date":"2014","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/25149275","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11311492","id":"PMC_11311492","title":"Association analysis of somatostatin receptor (SSTR1 and SSTR2) polymorphisms in breast cancer and solar keratosis.","date":"2001","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/11311492","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39361640","id":"PMC_39361640","title":"Selective ligand recognition and activation of somatostatin receptors SSTR1 and SSTR3.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/39361640","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29543369","id":"PMC_29543369","title":"Neuroanatomical connections between kisspeptin neurones and somatostatin neurones in female and male rat hypothalamus: a possible involvement of SSTR1 in kisspeptin release.","date":"2018","source":"Journal of neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29543369","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19140390","id":"PMC_19140390","title":"[Somatostatin receptors expression (SSTR1-SSTR5) in pheochromocytomas].","date":"2008","source":"Przeglad lekarski","url":"https://pubmed.ncbi.nlm.nih.gov/19140390","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7587644","id":"PMC_7587644","title":"Expression of sstr1 and sstr2 in rat hypothalamus: correlation with receptor binding and distribution of growth hormone regulatory peptides.","date":"1995","source":"Ciba Foundation symposium","url":"https://pubmed.ncbi.nlm.nih.gov/7587644","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11105212","id":"PMC_11105212","title":"Mapping of the CYP1A1, SSTR1 and TTF1 genes to pig chromosome 7q refines the porcine-human comparative map.","date":"2000","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11105212","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.03.17.643631","title":"Mechanisms of Activation and Serotonin release from Human Enterochromaffin Cells","date":"2025-03-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.17.643631","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1346068","id":"PMC_1346068","title":"Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1346068","citation_count":756,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10713101","id":"PMC_10713101","title":"Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10713101","citation_count":425,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12021920","id":"PMC_12021920","title":"Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis.","date":"2002","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12021920","citation_count":263,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9892225","id":"PMC_9892225","title":"Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis.","date":"1999","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/9892225","citation_count":254,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9125122","id":"PMC_9125122","title":"Identification and characterization of a novel human cortistatin-like peptide.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9125122","citation_count":136,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8405411","id":"PMC_8405411","title":"Distribution and second messenger coupling of four somatostatin receptor subtypes expressed in brain.","date":"1993","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8405411","citation_count":110,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20734064","id":"PMC_20734064","title":"A large-scale candidate gene association study of age at menarche and age at natural menopause.","date":"2010","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20734064","citation_count":106,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9205124","id":"PMC_9205124","title":"Cloning, mRNA expression, and chromosomal mapping of mouse and human preprocortistatin.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9205124","citation_count":97,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18240029","id":"PMC_18240029","title":"Reviews in molecular biology and biotechnology: transmembrane signaling by G protein-coupled receptors.","date":"2008","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/18240029","citation_count":92,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9886848","id":"PMC_9886848","title":"In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells.","date":"1999","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9886848","citation_count":86,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12788890","id":"PMC_12788890","title":"Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12788890","citation_count":84,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11344221","id":"PMC_11344221","title":"Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11344221","citation_count":82,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19086053","id":"PMC_19086053","title":"Identification of new putative susceptibility genes for several psychiatric disorders by association analysis of regulatory and non-synonymous SNPs of 306 genes involved in neurotransmission and neurodevelopment.","date":"2009","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19086053","citation_count":81,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15123239","id":"PMC_15123239","title":"An improved method for the synthesis of cellulose membrane-bound peptides with free C termini is useful for PDZ domain binding studies.","date":"2004","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/15123239","citation_count":75,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11527930","id":"PMC_11527930","title":"Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study.","date":"2001","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/11527930","citation_count":69,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18577758","id":"PMC_18577758","title":"Dissociation of heterotrimeric g proteins in cells.","date":"2008","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/18577758","citation_count":69,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19330452","id":"PMC_19330452","title":"Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.","date":"2009","source":"Pituitary","url":"https://pubmed.ncbi.nlm.nih.gov/19330452","citation_count":63,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15247250","id":"PMC_15247250","title":"The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15247250","citation_count":61,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7968260","id":"PMC_7968260","title":"Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines.","date":"1994","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/7968260","citation_count":61,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20810604","id":"PMC_20810604","title":"Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer.","date":"2010","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20810604","citation_count":59,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12376335","id":"PMC_12376335","title":"Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes.","date":"2002","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12376335","citation_count":58,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19318729","id":"PMC_19318729","title":"Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.","date":"2009","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/19318729","citation_count":56,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9279525","id":"PMC_9279525","title":"Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours.","date":"1997","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9279525","citation_count":56,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12474541","id":"PMC_12474541","title":"Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines.","date":"2002","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12474541","citation_count":54,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8449518","id":"PMC_8449518","title":"Human somatostatin receptor genes: localization to human chromosomes 14, 17, and 22 and identification of simple tandem repeat polymorphisms.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8449518","citation_count":52,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18347174","id":"PMC_18347174","title":"Identification of prognostic biomarkers for prostate cancer.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18347174","citation_count":51,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":27170,"output_tokens":4764,"usd":0.076485},"stage2":{"model":"claude-opus-4-6","input_tokens":8233,"output_tokens":3293,"usd":0.185235},"total_usd":0.666756,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":41564,"output_tokens":7870,"usd":0.121371},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11587,"output_tokens":5247,"usd":0.283665}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"SSTR1 couples to inhibition of adenylyl cyclase via pertussis toxin-sensitive G-proteins when stably expressed in CHO-K1 cells, and also stimulates inositol 1,4,5-trisphosphate formation through a pertussis toxin-sensitive pathway; Gi-alpha3 was identified as the dominant G-protein mediating adenylyl cyclase inhibition by SSTR1 using specific antisera.\",\n      \"method\": \"Stable expression in CHO cells, cAMP assay, IP3 measurement, pertussis toxin treatment, antisera against Gi-alpha subunits\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal functional assays with pharmacological dissection and G-protein subunit identification in a single study\",\n      \"pmids\": [\"7524497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SSTR1 couples to inhibition of adenylyl cyclase via pertussis toxin-sensitive G-proteins in CHO-K1 cells, independently confirmed in a second laboratory; SSTR2 but not SSTR1 may also couple to pertussis toxin-insensitive G-proteins based on GTPgammaS binding experiments.\",\n      \"method\": \"Stable expression in CHO-K1 cells, forskolin-stimulated cAMP assay, pertussis toxin pretreatment, GTPgammaS radioligand binding\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — replicated across independent labs with functional assays and pharmacological tools\",\n      \"pmids\": [\"7907016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SSTR1 stimulates phosphotyrosine phosphatase (PTP) activity in CHO-K1 cells stably expressing this receptor; activation has an EC50 of ~70 nM and is sensitive to pertussis toxin, indicating coupling through a Gi-type G-protein.\",\n      \"method\": \"Stable expression in CHO-K1 cells, phosphotyrosine phosphatase activity assay, pertussis toxin treatment\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct enzymatic assay with pertussis toxin dissection, replicated across labs\",\n      \"pmids\": [\"7854346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SSTR1 stimulates tyrosine phosphatase activity and inhibits cell proliferation in COS-7 and NIH 3T3 cells; RC-160 but not SMS-201-995 stimulated PTP activity through SSTR1 at concentrations consistent with their binding affinities, implicating tyrosine phosphatase as a transducer of SSTR1-mediated growth inhibition.\",\n      \"method\": \"Transient expression in COS-7 and NIH 3T3 cells, radioligand binding, tyrosine phosphatase assay, cell proliferation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods, replicated across cell lines, strong mechanistic correlation\",\n      \"pmids\": [\"7907795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SSTR1 uniquely mediates somatostatin inhibition of Na+/H+ exchange activity through a pertussis toxin-insensitive mechanism; chimeric receptor analysis mapped this function to a SSTR1 segment spanning the second through sixth hydrophobic domains including the second and third cytoplasmic loops.\",\n      \"method\": \"Stable expression in Ltk- fibroblasts and HEK293 cells, Na+/H+ exchange assay, chimeric receptor construction, pertussis toxin treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chimeric receptor mutagenesis combined with functional ion transport assay precisely mapping structural determinants\",\n      \"pmids\": [\"8144617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SSTR1 adenylyl cyclase inhibition is mediated by pertussis toxin-sensitive G-proteins; pharmacological identity established between native brain SS-2 binding sites and recombinant SSTR1, confirming SSTR1 as the molecular correlate of the SS-2 pharmacological class.\",\n      \"method\": \"Radioligand binding in HEK293 cells expressing recombinant SSTR1, adenylyl cyclase inhibition assay, pertussis toxin treatment, pharmacological correlation with native brain membranes\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional adenylyl cyclase assay combined with pharmacological profiling in recombinant system correlated with native tissue\",\n      \"pmids\": [\"7781706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"In pituitary GH12C1 and F4C1 cells, SSTR1 couples to inhibition of Ca2+ influx and membrane hyperpolarization via pertussis toxin-sensitive G-proteins, and mediates cAMP inhibition; SSTR1 does not activate phospholipase C, distinguishing it from SSTR2 which does activate PLC.\",\n      \"method\": \"Stable expression in pituitary cell lines, Ca2+ imaging, electrophysiology, cAMP assay, IP measurement, chimeric receptor construction, pertussis toxin treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal signaling assays with chimeric receptor domain-swap to map structural determinants of PLC coupling specificity\",\n      \"pmids\": [\"9228036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SSTR1 activates ERK/MAP kinase in CHO-K1 cells through a pertussis toxin-sensitive G-protein pathway requiring Ras, phosphatidylinositol 3-kinase, Raf-1, and the protein tyrosine phosphatase SHP-2; this ERK activation leads to increased expression of the CDK inhibitor p21(cip1/WAF1) and mediates antiproliferative effects of somatostatin.\",\n      \"method\": \"Stable expression in CHO-K1 cells, ERK kinase assay, dominant-negative Ras, PI3K inhibitor, pertussis toxin, SHP-2 dominant-negative, p21 Western blot, cell proliferation assay\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — pathway dissection with multiple dominant-negatives and pharmacological inhibitors, mechanistic endpoint (p21 induction)\",\n      \"pmids\": [\"9892010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SSTR1-mediated ERK activation involves beta-gamma subunits of pertussis toxin-sensitive G-proteins, Ras, Raf-1, PI3K, c-Src, and SHP-2; SHP-2 may activate c-Src by dephosphorylation, linking SSTR1's PTP-stimulatory activity to the ERK cascade and antiproliferative p21(cip1/WAF1) induction.\",\n      \"method\": \"Stable expression in CHO-K1 cells, ERK assay, kinase inhibitors, dominant-negatives, SHP-2 activation measurement\",\n      \"journal\": \"Journal of physiology, Paris\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic review synthesizing data from the same laboratory; no new independent replication\",\n      \"pmids\": [\"11088001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Asp137 in transmembrane domain 3 of SSTR1 forms an ion pair with the positively charged IAmp9 of the selective ligand CH275; Leu107 in TM2 of SSTR1 (vs. Phe in SSTR2) provides a hydrophobic interaction with the isopropyl group of IAmp9, determining subtype binding selectivity for CH275.\",\n      \"method\": \"Site-directed mutagenesis of SSTR1 (Asp137Asn, Leu107Phe), chimeric SSTR1/SSTR2 receptors, radioligand binding, microphysiometry (extracellular acidification rate)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis plus chimeric receptors with functional readout precisely map two key residues for ligand selectivity\",\n      \"pmids\": [\"10329447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SSTR1 activation causes a unique decrease in extracellular acidification rate (ECAR) in pituitary F4C1 cells via pertussis toxin-sensitive G-proteins, distinct from SSTR2's bidirectional ECAR response; both amiloride-sensitive and amiloride-insensitive Na+-dependent acid transport mechanisms contribute to SSTR1-mediated ECAR changes.\",\n      \"method\": \"Microphysiometry (Cytosensor), pertussis toxin pretreatment, Na+ removal, amiloride inhibitor, receptor-selective agonists in cells expressing individual SSTRs\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel subtype-specific functional readout with pharmacological dissection in a clean single-receptor system\",\n      \"pmids\": [\"10405760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A selective SSTR1 agonist (des-AA1,2,5[DTrp8,IAmp9]SRIF) was developed; its binding to SSTR1 is reduced by GTPgammaS in a pertussis toxin-preventable manner, indicating SSTR1 coupling to Gi-type G-proteins, and the ligand does not bind other SSTR subtypes.\",\n      \"method\": \"Radioligand binding competition assays in COS-7 cells expressing individual SSTR subtypes, GTPgammaS and pertussis toxin pharmacology\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective pharmacological tool developed with G-protein coupling validation\",\n      \"pmids\": [\"8786539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Double knockout of SSTR1 and SSTR5 in mice produces islet hyperplasia, hyperinsulinemia, and improved glucose tolerance, demonstrating that SSTR1 and SSTR5 together tonically suppress insulin secretion from pancreatic islets; loss of both receptors eliminates somatostatin-mediated inhibition of insulin release in isolated islets.\",\n      \"method\": \"SSTR1/SSTR5 double-knockout mice, intraperitoneal glucose tolerance test, isolated perfused pancreas model, islet culture, immunohistochemistry\",\n      \"journal\": \"Surgery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with multiple in vivo and ex vivo physiological readouts\",\n      \"pmids\": [\"15349106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SSTR1 knockout mice show altered glucose homeostasis: at 3 months, increased pancreatic insulin secretion ex vivo but decreased systemic insulin and glucose intolerance in vivo due to elevated insulin clearance; at 12 months, improved glucose tolerance with exaggerated insulin levels; knockout islets also show decreased somatostatin staining and reduced SSTR5 expression.\",\n      \"method\": \"SSTR1 knockout mouse model, glucose tolerance testing, isolated perfused pancreas, immunohistochemistry for SSTR5 and somatostatin\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with multiple complementary in vivo and ex vivo physiological assays\",\n      \"pmids\": [\"16406265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SSTR1 activation in C6 glioma cells in vivo mediates antiproliferative effects through phosphotyrosine phosphatase-dependent inhibition of ERK1/2 phosphorylation and upregulation of p27(Kip1); SSTR1 and SSTR2 agonists also reduce intratumoral neovascularization with synergistic effects when combined.\",\n      \"method\": \"Subcutaneous xenograft mouse model, selective SSTR agonists, immunohistochemistry for Ki-67, phospho-ERK1/2, p27Kip1, caspase-3, vessel density\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo pharmacological dissection with selective agonists and mechanistic endpoint markers\",\n      \"pmids\": [\"19706788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HOTAIR lncRNA binds the SSTR1 promoter and recruits DNA methyltransferases to increase SSTR1 methylation, reducing SSTR1 expression; reduced SSTR1 activates ERK1/2, enhancing dopaminergic neuron apoptosis in a PD cell model.\",\n      \"method\": \"ChIP, methylation analysis, HOTAIR overexpression/knockdown, SSTR1 overexpression/knockdown, ERK1/2 phosphorylation assay, apoptosis assay in MN9D cells and MPTP mouse model\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods (ChIP, methylation, gain/loss-of-function) from single lab establishing epigenetic regulation of SSTR1\",\n      \"pmids\": [\"32927363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of Gi-coupled SSTR1 activated by pasireotide and selective small-molecule agonist L-797591 reveal a conserved extended orthosteric binding pocket; mutagenesis identifies key residues determining ligand selectivity across SSTR subtypes; structures define the molecular mechanism of receptor activation including Gi coupling.\",\n      \"method\": \"Cryo-electron microscopy structure determination, site-directed mutagenesis, functional binding and signaling assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures combined with mutagenesis providing direct structural basis for ligand recognition and receptor activation\",\n      \"pmids\": [\"39361640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Upregulation of SSTR1 in neurons surrounding hematoma after intracerebral hemorrhage co-localizes with active caspase-3; SSTR1 knockdown in PC12 cells specifically reduces neuronal apoptosis, indicating SSTR1 promotes apoptosis and is coupled to reduced bcl-2 expression.\",\n      \"method\": \"Rat ICH model, Western blot, immunohistochemistry, double-label immunofluorescence, siRNA knockdown in PC12 cells, apoptosis assay\",\n      \"journal\": \"Cellular and molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — loss-of-function knockdown with apoptosis readout plus co-localization, single lab\",\n      \"pmids\": [\"25035058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SSTR1-expressing neuroendocrine cells suppress proliferation and sphere-formation of ALDH+ colon cancer stem cells via a paracrine mechanism in transwell co-culture; inhibition of SSTR1 signaling with cyclosomatostatin decreases cancer stem cell population and sphere-formation.\",\n      \"method\": \"Transwell co-culture, flow cytometry, sphere formation assay, proliferation assay, cyclosomatostatin pharmacological inhibition, exogenous somatostatin treatment\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — defined paracrine mechanism with pharmacological tool and co-culture functional assay, single lab\",\n      \"pmids\": [\"27927191\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SSTR1 is a Gi-coupled GPCR (with cryo-EM structural validation) that, upon somatostatin binding, inhibits adenylyl cyclase and activates phosphotyrosine phosphatase (particularly SHP-2) via pertussis toxin-sensitive G-proteins; uniquely among SSTR subtypes, it also inhibits Na+/H+ exchange through a pertussis toxin-insensitive pathway requiring its second and third cytoplasmic loops; SHP-2 activation links SSTR1 to ERK/MAP kinase activation (via Ras, PI3K, Raf-1, c-Src) and subsequent p21(cip1/WAF1) induction, mediating antiproliferative and antiangiogenic effects; in the pancreas, SSTR1 tonically suppresses insulin secretion, and its epigenetic silencing by HOTAIR-recruited DNA methyltransferases activates ERK1/2 to promote neuronal apoptosis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper and extract discoveries only from KEEP papers.\n\n**Classification summary:**\n- KEEP: Papers about canonical SSTR1 protein function (mechanistic studies)\n- EXCLUDE: Pure expression/IHC/prognostic papers, GWAS/association studies, papers about other genes, MGC cDNA collections, GO annotation tools, general GPCR reviews, caprine/sheep/pig SNP papers (animal breeding/genetics without mechanism)\n\nKey mechanistic papers to extract from:\n- PMID 7907795, 7854346, 9892010, 8144617, 9228036, 7524497, 7907016, 8786539, 10329447, 10405760, 10713101, 15247250, 11088001, 27927191, 15349106, 16406265, 39361640, 32927363, 25035058, 25149275, 19706788\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"SSTR1 was cloned and functionally characterized as a seven-transmembrane G protein-coupled receptor with 391 amino acids. Stably transfected CHO cells expressing SSTR1 exhibited specific, high-affinity somatostatin binding (higher affinity for somatostatin-14 than somatostatin-28), establishing SSTR1 as a bona fide somatostatin receptor.\",\n      \"method\": \"cDNA cloning, stable transfection in CHO cells, radioligand binding assays, RNA blotting\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning with functional expression, radioligand binding, and tissue distribution in multiple cell systems\",\n      \"pmids\": [\"1346068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"SSTR1 gene was chromosomally mapped to human chromosome 14q13, and a simple tandem repeat polymorphism was identified within the SSTR1 gene.\",\n      \"method\": \"Somatic cell hybrid panel segregation analysis, fluorescence in situ hybridization (FISH)\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two orthogonal mapping methods confirming chromosomal localization\",\n      \"pmids\": [\"8449518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Human SSTR1 stably expressed in HEK 293 cells couples to inhibition of forskolin-induced cAMP production, demonstrating functional coupling to adenylyl cyclase inhibition.\",\n      \"method\": \"Stable transfection in HEK293 cells, cAMP measurement assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional coupling in heterologous expression system, replicated across labs\",\n      \"pmids\": [\"8405411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SSTR1 stably expressed in CHO-K1 cells couples to inhibition of adenylyl cyclase via pertussis toxin-sensitive G proteins (Gi), and this coupling requires GTP. Specifically, antiserum against Giα3 (but not Giα1/Giα2) blocked SSTR1-mediated inhibition of adenylyl cyclase, identifying Giα3 as the dominant G protein coupling partner. SSTR1 additionally couples to stimulation of inositol 1,4,5-trisphosphate (IP3) formation, also through a pertussis toxin-sensitive mechanism.\",\n      \"method\": \"Stable transfection in CHO cells, cAMP and IP3 measurement assays, pertussis toxin pretreatment, specific Giα antiserum blockade\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal assays with specific antibody blockade identifying Giα3 as coupling partner\",\n      \"pmids\": [\"7524497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SSTR1 and SSTR2 stably expressed in CHO-K1 cells both inhibit adenylyl cyclase by approximately 35% via pertussis toxin-sensitive G proteins (Gi). Both SS14 and SS28 activate SSTR1 with high affinity (nanomolar ED50), whereas the synthetic analog MK678 does not activate SSTR1, establishing a pharmacological distinction between the two receptor subtypes.\",\n      \"method\": \"Stable transfection in CHO-K1 cells, adenylyl cyclase assay, pertussis toxin pretreatment, radioligand binding\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional coupling confirmed with pertussis toxin and GTP-dependence, replicated across labs\",\n      \"pmids\": [\"7907016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Somatostatin activation of SSTR1 stimulates phosphotyrosine phosphatase (PTP) activity in CHO-K1 cells with an EC50 of ~70 nM. This activation is sensitive to pertussis toxin. PTP stimulation in pituitary cell lines correlates with endogenous SSTR1 expression, suggesting SSTR1 couples to PTP stimulation as an effector pathway distinct from adenylyl cyclase inhibition.\",\n      \"method\": \"Stable transfection in CHO-K1 cells, phosphotyrosine phosphatase activity assay, pertussis toxin treatment, comparison with endogenous pituitary cell expression\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional assay in heterologous and endogenous cell systems with pertussis toxin validation\",\n      \"pmids\": [\"7854346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"SSTR1 and SSTR2 display distinct signaling properties when stably expressed in mouse fibroblast Ltk- or transiently in HEK293 cells. Both subtypes mediate somatostatin inhibition of cAMP via pertussis toxin-sensitive G proteins. However, only SSTR1 mediates somatostatin inhibition of Na+/H+ exchange activity, and this effect is pertussis toxin-insensitive. Chimeric receptor analysis localized the structural determinant for SSTR1-specific Na+/H+ exchanger coupling to sequences spanning the second through sixth hydrophobic domains (including second and third cytoplasmic loops), outside the third cytoplasmic loop alone.\",\n      \"method\": \"Stable and transient transfection, cAMP assay, Na+/H+ exchange activity assay, pertussis toxin treatment, chimeric receptor construction and functional analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chimeric receptor mutagenesis with multiple functional readouts identifying structural determinants of subtype-specific signaling\",\n      \"pmids\": [\"8144617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"In cells expressing SSTR1 or SSTR2, somatostatin analogues RC-160 and SMS-201-995 stimulate tyrosine phosphatase activity and inhibit serum-stimulated cell proliferation. In SSTR1-expressing cells, RC-160 (but not SMS-201-995) induced tyrosine phosphatase stimulation, consistent with RC-160's higher affinity for SSTR1. The correlation between receptor-binding affinity, tyrosine phosphatase stimulation, and antiproliferative potency implicates tyrosine phosphatase as a transducer of the SSTR1-mediated growth inhibition signal.\",\n      \"method\": \"Transfection in COS-7 and NIH 3T3 cells, radioligand competition binding assays, tyrosine phosphatase activity assay, cell proliferation assay (serum-stimulated), adenylyl cyclase assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional readouts in two cell systems with pharmacological correlation between binding affinity and functional potency\",\n      \"pmids\": [\"7907795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The first selective SSTR1 agonist, des-AA1,2,5-[DTrp8, IAmp9]SRIF (and its radiolabeled analog), was developed. This ligand binds human SSTR1 with an affinity of 1.8 nM (Kd ~0.5 nM) but does not bind other SSTR subtypes. GTPγS reduced binding of the selective analog to SSTR1 (an effect prevented by pertussis toxin), but did not affect SRIF binding to SSTR1, indicating the selective agonist binds SSTR1 in a functionally distinct, G protein-coupled conformation.\",\n      \"method\": \"Radioligand competition binding assays in COS-7 cells expressing human SSTR1, saturation binding, GTPγS and pertussis toxin modulation of binding\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — selective pharmacological tool development with G protein coupling validation and saturation binding characterization\",\n      \"pmids\": [\"8786539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"When SSTR1 and SSTR2 are individually expressed in rat pituitary GH12C1 and F4C1 cells lacking endogenous SSTRs: both couple to inhibition of Ca2+ influx and membrane hyperpolarization via pertussis toxin-sensitive G proteins; both mediate adenylyl cyclase inhibition via PTx-sensitive pathways; but only SSTR2 (not SSTR1) stimulates phospholipase C and increases intracellular Ca2+ from intracellular stores. Chimeric receptor analysis showed that sequences beyond the three intracellular loops (i.e., transmembrane domains) are required for SSTR2's unique PLC coupling.\",\n      \"method\": \"Stable transfection in pituitary GH12C1 and F4C1 cells lacking endogenous SSTRs, Ca2+ imaging, membrane potential measurements, cAMP assay, IP3/PLC assay, pertussis toxin treatment, chimeric receptor construction\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chimeric receptor mutagenesis with multiple functional assays in cell lines lacking endogenous receptors\",\n      \"pmids\": [\"9228036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SSTR1 stably expressed in CHO-K1 cells activates ERK (MAP kinase) in response to somatostatin, paradoxically augmenting fibroblast growth factor-stimulated ERK activity while antagonizing proliferation. SSTR1-mediated ERK activation requires: (1) pertussis toxin-sensitive Gβγ subunits, (2) Ras, (3) phosphatidylinositol 3-kinase, (4) Raf-1 kinase, and (5) the protein tyrosine phosphatase SHP-2. This ERK activation results in upregulation of the CDK inhibitor p21(cip1/WAF1), linking the SSTR1→SHP-2→ERK axis to the antiproliferative mechanism.\",\n      \"method\": \"Stable transfection in CHO-K1 cells, ERK activity assay (MAP kinase assay), pertussis toxin treatment, dominant-negative Ras and PI3K constructs, Raf-1 inhibition, SHP-2 manipulation, p21 immunoblotting\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic epistasis tools (dominant negatives) with defined pathway placement and molecular readout\",\n      \"pmids\": [\"9892010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Structural determinants of SSTR1-selective ligand binding were mapped using chimeric SSTR1/SSTR2 receptors and site-directed mutagenesis. Asp137 in transmembrane domain 3 (TM3) of SSTR1 forms an ion pair with the IAmp9 moiety of selective agonist CH275; mutation Asp137→Asn caused loss of binding and reduced potency. Leu107 in TM2 of SSTR1 provides a hydrophobic interaction with the isopropyl group of IAmp; Leu107→Phe substitution reduced CH275 affinity 20-fold without affecting SS affinity. Reciprocal Phe→Leu in a chimeric receptor restored CH275 affinity. These findings define Asp137 (TM3) and Leu107 (TM2) as key determinants of SSTR1 ligand selectivity.\",\n      \"method\": \"Chimeric SSTR1/SSTR2 receptor construction, site-directed mutagenesis (Asp137Asn, Leu107Phe), radioligand binding assays, microphysiometry (extracellular acidification rate)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reciprocal mutagenesis with functional validation identifies specific binding determinants\",\n      \"pmids\": [\"10329447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Using the silicon-based Cytosensor microphysiometer to measure extracellular acidification rate (ECAR) in pituitary F4C1 cells (lacking endogenous SSTRs), SSTR1 activation by somatostatin uniquely causes a decrease in ECAR (not previously observed for any receptor), while SSTR2 causes a biphasic ECAR response (increase then decrease). Both SSTR1- and SSTR2-mediated ECAR decreases are abolished by pertussis toxin. The ECAR responses involve both amiloride-sensitive and amiloride-insensitive Na+-dependent acid transport mechanisms, and removal of extracellular Na+ abolishes responses.\",\n      \"method\": \"Stable transfection in F4C1 pituitary cells, Cytosensor microphysiometry (ECAR measurement), pertussis toxin pretreatment, pharmacological inhibitors (methylisobutylamiloride), Na+-free conditions, receptor-selective agonists (MK678, CH275)\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — novel biosensor readout with pharmacological dissection in cells lacking endogenous SSTRs\",\n      \"pmids\": [\"10405760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"SSTR subtypes form homo- and heterodimers. Ligand activation induces SSTR1 homodimerization and SSTR1/SSTR5 heterodimerization as demonstrated by FRET analysis, pharmacological binding studies, and biochemical approaches. Dimerization alters functional properties including ligand binding affinity and agonist-induced receptor internalization. When SSTR1 and SSTR5 are coexpressed in CHO-K1 cells and treated with agonist, they internalize together into cytoplasmic vesicles. SSTR5 forms heterodimers with SSTR1 but not SSTR4, indicating selectivity of the heterodimerization process.\",\n      \"method\": \"Fluorescence resonance energy transfer (FRET), double-label confocal fluorescence microscopy, co-immunoprecipitation, pharmacological binding assays, transfected mutant and wild-type receptors in CHO-K1 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (FRET, confocal imaging, biochemistry) with functional consequences of dimerization\",\n      \"pmids\": [\"10713101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"SSTR1-mediated inhibition of cell proliferation in CHO-K1 cells correlates with activation of the MAP kinase cascade. The antiproliferative signal of SSTR1 requires Gβγ subunits from a pertussis toxin-sensitive G protein, Ras, Raf-1, PI3K, c-Src (a cytosolic tyrosine kinase), and SHP-2 (protein tyrosine phosphatase) to activate ERK. SHP-2 activates upstream kinases requiring tyrosine dephosphorylation (such as c-Src). Somatostatin and bFGF synergistically activate ERK via SSTR1, resulting in upregulation of p21cip/WAF1 as the molecular effector of antiproliferative activity.\",\n      \"method\": \"Stable transfection in CHO-K1 cells, ERK/MAP kinase activity assays, pertussis toxin, dominant-negative constructs for Ras/Raf/PI3K/c-Src/SHP-2, p21 expression analysis, proliferation assays\",\n      \"journal\": \"Journal of physiology, Paris\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic review of prior experimental data confirming SSTR1→Gβγ→Ras→Raf→PI3K→c-Src→SHP-2→ERK→p21 pathway, single lab\",\n      \"pmids\": [\"11088001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"SSTR1 selective activation by BIM-23926 in primary cultures from GH- and PRL-secreting human pituitary adenomas (expressing SSTR1 mRNA) inhibits GH secretion (~32%), PRL secretion (~20%), and reduces cell viability (~20%). The degree of inhibition correlates with SSTR1 mRNA levels, establishing a functional role for SSTR1 in suppressing hormone secretion and cell viability in pituitary adenoma cells.\",\n      \"method\": \"Primary culture of human pituitary adenoma cells, SSTR1-selective agonist (BIM-23926) treatment, RIA/hormone secretion assays, cell viability assay, quantitative RT-PCR for SSTR1 mRNA\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assay with selective pharmacological tool in primary human cells, single lab\",\n      \"pmids\": [\"12788890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Activation of hSSTR5 but not hSSTR1 is required for SSTR1/SSTR5 heterodimer formation. In cells co-expressing hSSTR1 and hSSTR5, treatment with SSTR5-selective agonist (but not SSTR1-selective agonist) induced heterodimerization, accompanied by increased adenylyl cyclase coupling efficiency. The C-terminal tail of hSSTR5 was identified as a structural determinant of heterodimer formation via chimeric receptor analysis. In contrast, hSSTR1 alone remains monomeric regardless of agonist treatment.\",\n      \"method\": \"Photobleaching FRET microscopy, Western blot, stable co-expression of hSSTR1 and hSSTR5 in live cells, C-tail chimeric receptors, adenylyl cyclase assay, subtype-selective agonist treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — pbFRET and Western blot with chimeric receptor mutagenesis identifying the C-tail of SSTR5 as the dimerization determinant\",\n      \"pmids\": [\"15247250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SSTR1 knockout mice display altered glucose homeostasis: at 3 months, SSTR1-/- mice have reduced body weight with growth retardation; isolated perfused pancreata show increased basal insulin secretion in vitro, but systemic insulin levels are decreased due to significantly higher insulin clearance rate; SSTR1-/- mice are glucose intolerant at 3 months but show increased glucose tolerance with exaggerated insulin response at 12 months. Immunohistochemistry showed decreased somatostatin staining and decreased SSTR5 expression in SSTR1-/- islets, suggesting SSTR1 regulates SSTR5 expression and coordinates insulin secretion and glucose homeostasis.\",\n      \"method\": \"SSTR1 knockout mouse model, intraperitoneal glucose tolerance test, isolated perfused pancreas model, islet culture, immunohistochemistry, insulin RIA\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with multiple physiological readouts across multiple ages\",\n      \"pmids\": [\"16406265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Double-gene ablation of SSTR1 and SSTR5 in mice results in islet hyperplasia, hyperinsulinemia, and improved glucose tolerance—a phenotype distinct from single-gene ablation of either receptor alone (which causes diabetes). SSTR1/5-/- islets show no response to somatostatin peptides in vitro, confirming ablation. Double-KO mice show increased basal and glucose-stimulated insulin secretion in vitro and exaggerated late-phase insulin secretion in vivo. This demonstrates that SSTR1 and SSTR5 act coordinately and non-redundantly to regulate insulin secretion and glucose homeostasis.\",\n      \"method\": \"SSTR1/SSTR5 double-knockout mouse generation, intraperitoneal glucose tolerance test, isolated perfused mouse pancreas, islet culture with somatostatin treatment, immunohistochemistry\",\n      \"journal\": \"Surgery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (double KO vs single KO) with multiple functional readouts establishing coordinate regulation\",\n      \"pmids\": [\"15349106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In C6 rat glioma cells in vivo (nude mouse xenograft model), selective SSTR1 agonist BIM-23745 inhibits tumor growth, reduces intratumoral neovascularization, suppresses Ki-67 expression, decreases ERK1/2 phosphorylation, and upregulates p27(Kip1). Combined activation of SSTR1 and SSTR2 (BIM-23704) shows synergistic antiproliferative and antiangiogenic activity exceeding SSTR5 agonist effects. Only modest caspase-3 activation is observed, indicating the mechanism is primarily cytostatic rather than apoptotic.\",\n      \"method\": \"Nude mouse C6 glioma xenograft model, selective SSTR1 agonist (BIM-23745) and bi-selective compounds, tumor growth measurement, immunohistochemistry for Ki-67, phospho-ERK1/2, p27Kip1, and caspase-3\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo loss/gain of function with selective pharmacological tools and molecular readouts, single lab\",\n      \"pmids\": [\"19706788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Following intracerebral hemorrhage (ICH) in adult rats, SSTR1 expression is markedly upregulated in neurons surrounding the hematoma. SSTR1 co-localizes with active caspase-3 (pro-apoptotic) and inversely with Bcl-2 (anti-apoptotic) in a time-dependent manner. Knockdown of SSTR1 in PC12 cells specifically reduces neuronal apoptosis. These data identify SSTR1 as a contributor to post-ICH neuronal apoptosis, coupled to caspase-3 activation and reduction of Bcl-2.\",\n      \"method\": \"Rat ICH model (caudate putamen), Western blot, immunohistochemistry, double-labeled immunofluorescence, SSTR1 siRNA knockdown in PC12 cells, behavioral testing\",\n      \"journal\": \"Cellular and molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — in vivo model with knockdown validation in cell culture; single lab with co-localization and functional readout\",\n      \"pmids\": [\"25035058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In colorectal cancer (CRC), SSTR1-expressing neuroendocrine cells regulate cancer stem cell (ALDH+) quiescence via paracrine signaling. When SSTR1+ cells are co-cultured with ALDH+ cancer stem cells in transwell assays, sphere formation and proliferation of ALDH+ cells are inhibited. ALDH+ cells themselves lack SST and SSTR1 expression, confirming the paracrine mechanism. Inhibition of SSTR1 signaling by cycloSST (a somatostatin antagonist) decreases ALDH+ cell population size and sphere formation, and the ALDH+/SSTR1+ ratio inversely correlates with growth dynamics.\",\n      \"method\": \"Flow cytometry (ALDH, SSTR1 quantification), transwell co-culture assays, sphere formation assay, proliferation assay (doubling time), exogenous SST and cycloSST treatment, primary normal/tumor tissue analysis, CRC cell lines\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — transwell paracrine assay with pharmacological manipulation; multiple CRC cell lines and primary tissue but single lab\",\n      \"pmids\": [\"27927191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In a MPTP-induced Parkinson's disease mouse model and MPP+-treated MN9D dopaminergic cells, the lncRNA HOTAIR is upregulated while SSTR1 is downregulated. HOTAIR binds to the SSTR1 promoter and recruits DNA methyltransferases to increase SSTR1 promoter methylation, thereby suppressing SSTR1 expression. Overexpression of HOTAIR or silencing of SSTR1 enhances dopaminergic neuron apoptosis and exacerbates dyskinesia; conversely, reduced HOTAIR/restored SSTR1 is neuroprotective. The downstream effect of SSTR1 suppression operates through activation of the ERK1/2 signaling axis.\",\n      \"method\": \"MPTP mouse model and MPP+ cell model of PD, HOTAIR overexpression/knockdown, SSTR1 knockdown/overexpression, chromatin immunoprecipitation (ChIP) for HOTAIR binding to SSTR1 promoter, bisulfite sequencing for methylation, Western blot (ERK1/2), cell viability and apoptosis assays, behavioral testing\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and methylation analysis with epistatic rescue experiments linking HOTAIR→SSTR1 methylation→ERK1/2→apoptosis; single lab\",\n      \"pmids\": [\"32927363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of Gi-coupled SSTR1 were determined bound to the FDA-approved panagonist pasireotide and the SSTR1-selective small molecule agonist L-797591. The structures reveal that pasireotide occupies an extended binding pocket conserved across SSTRs, distinct from the binding mode of SST14, octreotide, and lanreotide. The SSTR1 orthosteric pocket accommodates divergent agonists through dynamic conformational changes. Key residues determining SSTR1 vs. SSTR3 ligand selectivity were identified across the orthosteric pocket, and mutagenesis analyses validated these structural determinants. The structures also reveal the molecular mechanism of receptor activation and G protein coupling.\",\n      \"method\": \"Cryo-electron microscopy (cryo-EM) structure determination of Gi-coupled SSTR1 and SSTR3, site-directed mutagenesis, functional assays validating binding and activation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures with mutagenesis validation, revealing molecular basis of ligand recognition and receptor activation\",\n      \"pmids\": [\"39361640\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SSTR1 is a seven-transmembrane Gi-coupled receptor (primarily Giα3) that, upon somatostatin binding, inhibits adenylyl cyclase and stimulates phosphotyrosine phosphatase (PTP) activity—including SHP-2—which in turn activates a Gβγ→Ras→PI3K→c-Src→Raf-1→ERK cascade leading to p21(cip1/WAF1) upregulation and cell growth arrest; uniquely among SSTRs, SSTR1 also inhibits Na+/H+ exchange via a pertussis toxin-insensitive mechanism, can form selective heterodimers with SSTR5 (requiring SSTR5 C-tail conformational changes) that alter receptor signaling and internalization, and plays an essential role in pancreatic insulin secretion and glucose homeostasis as demonstrated by knockout models; structural basis for its ligand recognition has been revealed by cryo-EM structures showing a conserved extended binding pocket with SSTR1-specific residues (Asp137 in TM3, Leu107 in TM2) governing selective agonist accommodation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SSTR1 is a Gi-coupled somatostatin receptor that transduces antiproliferative, ion transport, and neuroendocrine inhibitory signals through multiple effector pathways. Ligand binding activates pertussis toxin-sensitive Gi proteins (predominantly Giα3) to inhibit adenylyl cyclase, stimulate the tyrosine phosphatase SHP-2, and suppress Ca²⁺ influx; SHP-2 activation feeds into ERK/MAPK signaling via Ras, PI3K, Raf-1, and c-Src, ultimately inducing the CDK inhibitors p21(Cip1/WAF1) and p27(Kip1) to arrest proliferation [PMID:7524497, PMID:9892010, PMID:19706788]. Uniquely among SSTR subtypes, SSTR1 also inhibits Na⁺/H⁺ exchange through a pertussis toxin-insensitive mechanism mapped to its second and third cytoplasmic loops [PMID:8144617]. In pancreatic islets, SSTR1 together with SSTR5 tonically suppresses insulin secretion, as demonstrated by hyperinsulinemia and islet hyperplasia in double-knockout mice [PMID:15349106, PMID:16406265].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"The primary signal transduction pathway of SSTR1 was established: Gi-protein-dependent inhibition of adenylyl cyclase, with Giα3 identified as the dominant coupling partner, resolving which G-protein subtype mediates SSTR1 signaling.\",\n      \"evidence\": \"Stable expression in CHO-K1 cells with cAMP assays, pertussis toxin treatment, and Giα-subunit-specific antisera, replicated independently across laboratories\",\n      \"pmids\": [\"7524497\", \"7907016\", \"7781706\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous tissue validation of Giα3 preference\", \"Contribution of other Giα isoforms not excluded\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"SSTR1 was shown to stimulate phosphotyrosine phosphatase activity and inhibit cell proliferation, establishing a direct link between somatostatin receptor activation and growth-inhibitory tyrosine dephosphorylation.\",\n      \"evidence\": \"PTP enzymatic assays in CHO-K1, COS-7, and NIH 3T3 cells with pertussis toxin sensitivity and correlation to antiproliferative effects\",\n      \"pmids\": [\"7854346\", \"7907795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the specific PTP isoform was not yet determined\", \"Downstream substrates of PTP unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"A pertussis toxin-insensitive pathway unique to SSTR1 was discovered — inhibition of Na⁺/H⁺ exchange — and the structural determinants were mapped to a segment spanning the second and third cytoplasmic loops, revealing a subtype-specific effector coupling mechanism.\",\n      \"evidence\": \"Chimeric SSTR1/SSTR2 receptor analysis in Ltk⁻ fibroblasts and HEK293 cells with Na⁺/H⁺ exchange functional assays\",\n      \"pmids\": [\"8144617\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"G-protein or adaptor mediating PTX-insensitive NHE inhibition unidentified\", \"Physiological relevance in native tissues not tested\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"In pituitary cells, SSTR1 was shown to inhibit Ca²⁺ influx and hyperpolarize membranes via PTX-sensitive G-proteins but not activate PLC, distinguishing its signaling repertoire from SSTR2 and defining subtype-specific effector coupling in an endocrine context.\",\n      \"evidence\": \"Stable expression in pituitary GH12C1/F4C1 cells with Ca²⁺ imaging, electrophysiology, cAMP, and IP measurements combined with chimeric receptor domain-swap\",\n      \"pmids\": [\"9228036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"K⁺ channel identity downstream of SSTR1 not determined\", \"Whether SSTR1 couples to PLC in any native tissue remains open\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The full ERK/MAPK signaling cascade downstream of SSTR1 was dissected — SHP-2 activation links via c-Src, Ras, PI3K, and Raf-1 to ERK, inducing p21(Cip1/WAF1) — thereby connecting SSTR1's PTP-stimulatory activity to a defined antiproliferative mechanism.\",\n      \"evidence\": \"Dominant-negative Ras, PI3K inhibitors, SHP-2 dominant-negative, and Western blots for p21 in CHO-K1 cells\",\n      \"pmids\": [\"9892010\", \"11088001\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct SHP-2 dephosphorylation of c-Src not biochemically demonstrated\", \"Relevance of this cascade in primary tumor cells not tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Key ligand-binding residues were identified — Asp137 in TM3 forms an ion pair with selective agonist CH275 and Leu107 in TM2 confers subtype selectivity — providing the first molecular-level understanding of SSTR1 pharmacological selectivity.\",\n      \"evidence\": \"Site-directed mutagenesis (D137N, L107F), chimeric receptors, radioligand binding, and microphysiometry\",\n      \"pmids\": [\"10329447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full three-dimensional structural context at this time\", \"Interactions with endogenous somatostatin peptides not mapped at residue level\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Genetic knockout studies established that SSTR1 and SSTR5 together mediate tonic somatostatin inhibition of insulin secretion in vivo, with double-knockout mice showing islet hyperplasia and hyperinsulinemia.\",\n      \"evidence\": \"SSTR1/SSTR5 double-knockout mice with glucose tolerance tests, isolated perfused pancreas, and islet immunohistochemistry\",\n      \"pmids\": [\"15349106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contributions of SSTR1 versus SSTR5 to insulin suppression not fully resolved\", \"Downstream β-cell signaling pathway not characterized\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Single SSTR1 knockout mice revealed age-dependent roles in glucose homeostasis and compensatory changes in islet SSTR5 and somatostatin expression, demonstrating SSTR1's non-redundant contribution to endocrine pancreas physiology.\",\n      \"evidence\": \"SSTR1 knockout mouse with longitudinal glucose tolerance testing, perfused pancreas, and immunohistochemistry\",\n      \"pmids\": [\"16406265\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of increased insulin clearance in young KO mice unknown\", \"Cross-talk with other islet SSTRs at the signaling level unexplored\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"In vivo antitumor and antiangiogenic activity of SSTR1 was demonstrated in glioma xenografts, mediated through PTP-dependent ERK1/2 inhibition and p27(Kip1) upregulation, extending the antiproliferative mechanism beyond cell lines.\",\n      \"evidence\": \"C6 glioma subcutaneous xenograft model with selective SSTR1 agonist, immunohistochemistry for phospho-ERK1/2, p27, Ki-67, caspase-3, and vessel density\",\n      \"pmids\": [\"19706788\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PTP activation not measured in vivo\", \"Antiangiogenic mechanism (direct on endothelium vs. indirect) not dissected\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"SSTR1 was implicated in promoting neuronal apoptosis after brain injury, with SSTR1 knockdown reducing caspase-3 activation and apoptosis, suggesting context-dependent pro-apoptotic signaling.\",\n      \"evidence\": \"Rat intracerebral hemorrhage model, co-localization with active caspase-3, siRNA knockdown in PC12 cells\",\n      \"pmids\": [\"25035058\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway linking SSTR1 to apoptosis in neurons not defined\", \"Apparent contradiction with antiproliferative/survival roles in other contexts unresolved\", \"Single laboratory finding\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Epigenetic silencing of SSTR1 was shown to occur via HOTAIR lncRNA-recruited DNA methyltransferases, with reduced SSTR1 leading to ERK1/2 activation and dopaminergic neuron apoptosis in a Parkinson's disease model — revealing a transcriptional regulatory mechanism for SSTR1.\",\n      \"evidence\": \"ChIP, promoter methylation analysis, HOTAIR gain/loss-of-function, ERK phosphorylation assay, apoptosis assay in MN9D cells and MPTP mouse model\",\n      \"pmids\": [\"32927363\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether SSTR1 methylation occurs in human PD patients unknown\", \"Specific DNMT isoform recruited not identified\", \"Mechanism by which SSTR1 loss activates ERK in this context not reconciled with ERK activation by SSTR1 signaling in other systems\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Cryo-EM structures of Gi-coupled SSTR1 with two different ligands provided the first atomic-resolution view of receptor activation and Gi coupling, defining the orthosteric pocket and residues governing subtype selectivity — a structural framework for drug design.\",\n      \"evidence\": \"Cryo-EM structure determination with pasireotide and L-797591, combined with site-directed mutagenesis and functional assays\",\n      \"pmids\": [\"39361640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inactive-state structure not determined\", \"Structural basis for PTX-insensitive NHE coupling still unknown\", \"Biased agonism at structural level unexplored\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The identity of the G-protein or adaptor mediating SSTR1's pertussis toxin-insensitive inhibition of Na⁺/H⁺ exchange remains unknown, and the structural basis for SSTR1's unique effector coupling repertoire (distinct from other SSTRs) has not been resolved despite available cryo-EM structures.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PTX-insensitive pathway mediator unidentified\", \"No structure of SSTR1 in complex with non-Gi effectors\", \"Reconciliation of pro-apoptotic versus antiproliferative signaling across cell types mechanistically unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 5, 6, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 3, 7, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 6, 9, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 2, 6, 7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 6, 7]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 3, 7, 14]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [15, 17]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [12, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GNAI3\",\n      \"PTPN11\",\n      \"KRAS\",\n      \"PIK3CA\",\n      \"RAF1\",\n      \"SRC\",\n      \"HOTAIR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"SSTR1 is a Gi-coupled somatostatin receptor that transduces antiproliferative, secretory-inhibitory, and metabolic signals through multiple effector pathways. Upon somatostatin binding, SSTR1 inhibits adenylyl cyclase via pertussis toxin-sensitive Giα3 and stimulates phosphotyrosine phosphatase (SHP-2) activity, which feeds into a Gβγ→Ras→PI3K→c-Src→Raf-1→ERK cascade culminating in p21(cip1/WAF1) upregulation and cell-cycle arrest [PMID:9892010, PMID:7524497, PMID:7854346]. Uniquely among somatostatin receptors, SSTR1 inhibits Na⁺/H⁺ exchange through a pertussis toxin-insensitive mechanism structurally mapped to transmembrane domains 2–6, forms selective ligand-dependent heterodimers with SSTR5 that alter signaling efficiency, and coordinates with SSTR5 to regulate pancreatic insulin secretion and glucose homeostasis as demonstrated by single- and double-knockout mouse models [PMID:8144617, PMID:10713101, PMID:15349106, PMID:16406265]. Cryo-EM structures of Gi-coupled SSTR1 bound to pasireotide and the SSTR1-selective agonist L-797591 reveal an extended orthosteric pocket with subtype-specific residues including Asp137 (TM3) and Leu107 (TM2) governing selective agonist accommodation [PMID:39361640, PMID:10329447].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Molecular cloning of SSTR1 established it as a 391-amino-acid seven-transmembrane receptor with high-affinity somatostatin binding, resolving the molecular identity of somatostatin receptor subtypes.\",\n      \"evidence\": \"cDNA cloning with stable expression in CHO cells and radioligand binding assays\",\n      \"pmids\": [\"1346068\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No effector coupling or signaling pathway identified\", \"Tissue-specific function unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Functional coupling studies revealed that SSTR1 inhibits adenylyl cyclase via Giα3, stimulates phosphotyrosine phosphatase activity, and—uniquely among SSTRs—inhibits Na⁺/H⁺ exchange through a pertussis toxin-insensitive mechanism, establishing SSTR1 as a multi-effector receptor with subtype-specific signaling.\",\n      \"evidence\": \"Heterologous expression in CHO-K1 and Ltk⁻ cells with cAMP, PTP, and NHE assays; Giα-specific antiserum blockade; chimeric receptor analysis localizing NHE coupling to TM2-TM6 domains\",\n      \"pmids\": [\"7524497\", \"7854346\", \"8144617\", \"7907795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the specific phosphotyrosine phosphatase was not determined\", \"Molecular mechanism of PTx-insensitive NHE coupling unresolved\", \"Downstream consequences of PTP activation for cell fate unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The antiproliferative signaling cascade downstream of SSTR1 was delineated as a Gβγ→Ras→PI3K→c-Src→Raf-1→ERK pathway dependent on SHP-2, culminating in p21(cip1/WAF1) upregulation and cell-cycle arrest, resolving the paradox of growth-inhibitory ERK activation.\",\n      \"evidence\": \"Dominant-negative constructs for Ras, Raf, PI3K, c-Src, and SHP-2 in stably transfected CHO-K1 cells with ERK activity and p21 immunoblotting\",\n      \"pmids\": [\"9892010\", \"11088001\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pathway validated only in CHO-K1 cells; relevance to endogenous SSTR1-expressing tissues not confirmed\", \"Mechanism by which SHP-2 activates c-Src not fully defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Mutagenesis identified Asp137 in TM3 and Leu107 in TM2 as critical determinants of SSTR1-selective agonist recognition, providing the first structural basis for receptor subtype selectivity.\",\n      \"evidence\": \"Chimeric SSTR1/SSTR2 receptors and site-directed mutagenesis with radioligand binding and microphysiometry in transfected cells\",\n      \"pmids\": [\"10329447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structural data at this time\", \"Additional residues contributing to full selectivity profile unexplored\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Discovery that SSTR1 forms ligand-induced homodimers and selective heterodimers with SSTR5 (but not SSTR4), with heterodimerization altering binding affinity and co-internalization, established receptor oligomerization as a regulatory mechanism for SSTR signaling.\",\n      \"evidence\": \"FRET, co-immunoprecipitation, and confocal microscopy in CHO-K1 cells co-expressing tagged receptors\",\n      \"pmids\": [\"10713101\", \"15247250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of heterodimerization in native tissues not demonstrated\", \"Downstream signaling consequences of dimers vs. monomers incompletely characterized\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Single and double knockout of SSTR1 and SSTR5 in mice revealed non-redundant, coordinate regulation of insulin secretion and glucose homeostasis, establishing an essential physiological role for SSTR1 in pancreatic endocrine function.\",\n      \"evidence\": \"SSTR1⁻/⁻ and SSTR1/5⁻/⁻ mice with glucose tolerance tests, perfused pancreas, islet culture, and immunohistochemistry\",\n      \"pmids\": [\"16406265\", \"15349106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which SSTR1 loss alters SSTR5 expression unknown\", \"Human relevance of knockout phenotypes not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"In vivo anti-tumor activity of SSTR1 was demonstrated in glioma xenografts, where selective SSTR1 activation suppressed tumor growth, neovascularization, and ERK phosphorylation while upregulating p27(Kip1), confirming cytostatic rather than apoptotic mechanisms.\",\n      \"evidence\": \"Nude mouse C6 glioma xenograft with SSTR1-selective agonist BIM-23745, immunohistochemistry for Ki-67, p-ERK, p27, and caspase-3\",\n      \"pmids\": [\"19706788\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single tumor model and single lab\", \"Antiangiogenic mechanism not molecularly defined\", \"Switch from ERK-dependent p21 (CHO cells) to p27 (glioma) upregulation unexplained\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Cryo-EM structures of Gi-coupled SSTR1 bound to pasireotide and L-797591 revealed the atomic basis of the orthosteric binding pocket, confirming mutagenesis-predicted selectivity determinants and providing a structural framework for subtype-selective drug design.\",\n      \"evidence\": \"Cryo-EM structure determination with site-directed mutagenesis validation and functional assays\",\n      \"pmids\": [\"39361640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of SSTR1 in apo or antagonist-bound state\", \"Structural basis of SSTR1/SSTR5 heterodimerization unknown\", \"Mechanism of PTx-insensitive NHE coupling not structurally resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for SSTR1's unique pertussis toxin-insensitive coupling to Na⁺/H⁺ exchange, the physiological significance of SSTR1/SSTR5 heterodimerization in native human tissues, and the molecular mechanism by which SSTR1 loss alters SSTR5 expression in pancreatic islets.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model for PTx-insensitive NHE pathway coupling\", \"SSTR1/SSTR5 heterodimer not demonstrated in native tissue\", \"Human genetic studies linking SSTR1 variants to metabolic disease absent\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 3, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 7, 10, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 13, 16]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [3, 10, 14, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 10, 14, 23]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [13, 16]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [17, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"SSTR5\",\n      \"GNAI3\",\n      \"PTPN11\",\n      \"SRC\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway term_ids. I used an incorrect GO term. Let me correct:\n\n```json\n{\n  \"mechanistic_narrative\": \"SSTR1 is a Gi-coupled somatostatin receptor that transduces antiproliferative, secretory-inhibitory, and metabolic signals through multiple effector pathways. Upon somatostatin binding, SSTR1 inhibits adenylyl cyclase via pertussis toxin-sensitive Giα3 and stimulates phosphotyrosine phosphatase (SHP-2) activity, which feeds into a Gβγ→Ras→PI3K→c-Src→Raf-1→ERK cascade culminating in p21(cip1/WAF1) upregulation and cell-cycle arrest [PMID:9892010, PMID:7524497, PMID:7854346]. Uniquely among somatostatin receptors, SSTR1 inhibits Na⁺/H⁺ exchange through a pertussis toxin-insensitive mechanism structurally mapped to transmembrane domains 2–6, forms selective ligand-dependent heterodimers with SSTR5 that alter signaling efficiency, and coordinates with SSTR5 to regulate pancreatic insulin secretion and glucose homeostasis as demonstrated by single- and double-knockout mouse models [PMID:8144617, PMID:10713101, PMID:15349106, PMID:16406265]. Cryo-EM structures of Gi-coupled SSTR1 bound to pasireotide and the SSTR1-selective agonist L-797591 reveal an extended orthosteric pocket with subtype-specific residues including Asp137 (TM3) and Leu107 (TM2) governing selective agonist accommodation [PMID:39361640, PMID:10329447].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Molecular cloning of SSTR1 established it as a 391-amino-acid seven-transmembrane receptor with high-affinity somatostatin binding, resolving the molecular identity of somatostatin receptor subtypes.\",\n      \"evidence\": \"cDNA cloning with stable expression in CHO cells and radioligand binding assays\",\n      \"pmids\": [\"1346068\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No effector coupling or signaling pathway identified\", \"Tissue-specific function unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Functional coupling studies revealed that SSTR1 inhibits adenylyl cyclase via Giα3, stimulates phosphotyrosine phosphatase activity, and—uniquely among SSTRs—inhibits Na⁺/H⁺ exchange through a pertussis toxin-insensitive mechanism, establishing SSTR1 as a multi-effector receptor with subtype-specific signaling.\",\n      \"evidence\": \"Heterologous expression in CHO-K1 and Ltk⁻ cells with cAMP, PTP, and NHE assays; Giα-specific antiserum blockade; chimeric receptor analysis localizing NHE coupling to TM2-TM6 domains\",\n      \"pmids\": [\"7524497\", \"7854346\", \"8144617\", \"7907795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the specific phosphotyrosine phosphatase was not determined\", \"Molecular mechanism of PTx-insensitive NHE coupling unresolved\", \"Downstream consequences of PTP activation for cell fate unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The antiproliferative signaling cascade downstream of SSTR1 was delineated as a Gβγ→Ras→PI3K→c-Src→Raf-1→ERK pathway dependent on SHP-2, culminating in p21(cip1/WAF1) upregulation and cell-cycle arrest, resolving the paradox of growth-inhibitory ERK activation.\",\n      \"evidence\": \"Dominant-negative constructs for Ras, Raf, PI3K, c-Src, and SHP-2 in stably transfected CHO-K1 cells with ERK activity and p21 immunoblotting\",\n      \"pmids\": [\"9892010\", \"11088001\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pathway validated only in CHO-K1 cells; relevance to endogenous SSTR1-expressing tissues not confirmed\", \"Mechanism by which SHP-2 activates c-Src not fully defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Mutagenesis identified Asp137 in TM3 and Leu107 in TM2 as critical determinants of SSTR1-selective agonist recognition, providing the first structural basis for receptor subtype selectivity.\",\n      \"evidence\": \"Chimeric SSTR1/SSTR2 receptors and site-directed mutagenesis with radioligand binding and microphysiometry in transfected cells\",\n      \"pmids\": [\"10329447\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structural data at this time\", \"Additional residues contributing to full selectivity profile unexplored\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Discovery that SSTR1 forms ligand-induced homodimers and selective heterodimers with SSTR5 (but not SSTR4), with heterodimerization altering binding affinity and co-internalization, established receptor oligomerization as a regulatory mechanism for SSTR signaling.\",\n      \"evidence\": \"FRET, co-immunoprecipitation, and confocal microscopy in CHO-K1 cells co-expressing tagged receptors\",\n      \"pmids\": [\"10713101\", \"15247250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of heterodimerization in native tissues not demonstrated\", \"Downstream signaling consequences of dimers vs. monomers incompletely characterized\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Single and double knockout of SSTR1 and SSTR5 in mice revealed non-redundant, coordinate regulation of insulin secretion and glucose homeostasis, establishing an essential physiological role for SSTR1 in pancreatic endocrine function.\",\n      \"evidence\": \"SSTR1⁻/⁻ and SSTR1/5⁻/⁻ mice with glucose tolerance tests, perfused pancreas, islet culture, and immunohistochemistry\",\n      \"pmids\": [\"16406265\", \"15349106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which SSTR1 loss alters SSTR5 expression unknown\", \"Human relevance of knockout phenotypes not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"In vivo anti-tumor activity of SSTR1 was demonstrated in glioma xenografts, where selective SSTR1 activation suppressed tumor growth, neovascularization, and ERK phosphorylation while upregulating p27(Kip1), confirming cytostatic rather than apoptotic mechanisms.\",\n      \"evidence\": \"Nude mouse C6 glioma xenograft with SSTR1-selective agonist BIM-23745, immunohistochemistry for Ki-67, p-ERK, p27, and caspase-3\",\n      \"pmids\": [\"19706788\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single tumor model and single lab\", \"Antiangiogenic mechanism not molecularly defined\", \"Switch from ERK-dependent p21 (CHO cells) to p27 (glioma) upregulation unexplained\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Cryo-EM structures of Gi-coupled SSTR1 bound to pasireotide and L-797591 revealed the atomic basis of the orthosteric binding pocket, confirming mutagenesis-predicted selectivity determinants and providing a structural framework for subtype-selective drug design.\",\n      \"evidence\": \"Cryo-EM structure determination with site-directed mutagenesis validation and functional assays\",\n      \"pmids\": [\"39361640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of SSTR1 in apo or antagonist-bound state\", \"Structural basis of SSTR1/SSTR5 heterodimerization unknown\", \"Mechanism of PTx-insensitive NHE coupling not structurally resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for SSTR1's unique pertussis toxin-insensitive coupling to Na⁺/H⁺ exchange, the physiological significance of SSTR1/SSTR5 heterodimerization in native human tissues, and the molecular mechanism by which SSTR1 loss alters SSTR5 expression in pancreatic islets.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model for PTx-insensitive NHE pathway coupling\", \"SSTR1/SSTR5 heterodimer not demonstrated in native tissue\", \"Human genetic studies linking SSTR1 variants to metabolic disease absent\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 3, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 7, 10, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 13, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 10, 14, 23]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [13, 16]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [17, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"SSTR5\",\n      \"GNAI3\",\n      \"PTPN11\",\n      \"SRC\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}